PTX secures EU Authorisation to commence PTX-100 Trial

MELBOURNE, Australia – 15 December 2025 – Prescient Therapeutics Limited (ASX: PTX), a clinical-stage oncology company developing targeted cancer therapies today announced that the European Clinical Trials Information System (CTIS), has granted authorisation to initiate its PTX-100 clinical trial in patients with relapsed/refractory Cutaneous T-cell Lymphoma (CTCL) in Italy. This approval allows P